PI
YMAB

Putnam Investments’s Y-mAbs Therapeutics YMAB Stock Holding History

Putnam Investments’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-115,202
Closed -$5.7M – 849
2020
Q4 		$5.7M Buy
115,202
+2,769
+2% +$128K 0.01% 476
2020
Q3 		$4.32M Buy
112,433
+7,393
+7% +$294K 0.01% 509
2020
Q2 		$4.54M Buy
105,040
+16,920
+19% +$640K 0.01% 486
2020
Q1 		$2.3M Sell
88,120
-135,632
-61% -$3.94M 0.01% 582
2019
Q4 		$6.99M Buy
223,752
+113,352
+103% +$3.35M 0.01% 447
2019
Q3 		$2.88M Buy
+110,400
New +$2.82M 0.01% 643

Other funds holding YMAB

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Putnam Investments's YMAB Position: Q1 2021 in Review

Putnam Investments sold out of Y-mAbs Therapeutics (YMAB) in Q1 2021, closing a stake of 115,202 shares — an estimated $5.7M sold.

Putnam Investments first reported a position in YMAB in Q3 2019 and held it in 6 quarters. The position peaked at $6.99M in Q4 2019. 117 funds tracked by Wall St. Rank hold YMAB as of Q1 2021.

  • Putnam Investments reported no remaining Y-mAbs Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Putnam Investments sold 115,202 Y-mAbs Therapeutics shares in Q1 2021, an estimated $5.7M.
  • Putnam Investments first reported a position in Y-mAbs Therapeutics in Q3 2019 and held it in 6 quarters.
  • Putnam Investments's Y-mAbs Therapeutics position peaked at $6.99M in Q4 2019.
  • 117 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2021.

Based on Putnam Investments's 13F filing for Q1 2021, filed 17 May 2021.